Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Moderna stock tumbled after the Senate Finance Committee voted to send RFK Jr.'s nomination for the HHS secretary to the full ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said it ...

Major stock indexes closed higher/lower on Friday, after the week saw a flurry of events including DeepSeek scare and ...

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Moderna's RSV vaccine earned approval last May, but sales haven't gotten off the ground yet. The biotech company expects to lose money again in 2025, but operating expenses are declining.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...